The 16 (76%) others patients received antitumoral treatment (Table 2), which consisted of induction chemotherapy (anthracycline‐cytarabine–based regimen; n = 5/16, 31%), hypomethylating agents (n = 5/16 including one MDS, 31%), imatinib (n = 2/16, 13%), IDH1/2 inhibitors (n = 2/16, 13%), FLT3 inhibitor (n = 1/16, 6%) and venetoclax (n = 1/16, 6%). The gene discussed is IDH1; the disease is myelodysplastic syndrome.